atai Life Sciences

News

Psychedelic merger to create AtaiBeckley completes

A $390m merger of two pioneers of psychedelic medicines has completed to create AtaiBeckley, with a pipeline of candidates for mental illnesses.

News

Beckley psychedelic hits the target, unlocking atai merger

The proposed merger between Beckley Psytech and atai can go ahead as a psychedelic for depression hits all its endpoints in a phase 2b trial.

News

Consolidation in psychedelics as atai pairs with Beckley

Beckley Psytech has agreed to merge with atai Life Sciences in a deal that would bring together two psychedelic medicine pioneers.

News

atai invests $50m in Beckley Psytech

Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinica

Psychedelic merger to create AtaiBeckley completes

Beckley psychedelic hits the target, unlocking atai merger

Consolidation in psychedelics as atai pairs with Beckley

atai invests $50m in Beckley Psytech

LSX2026: On a therapeutic vision for ocular disease, with Al...

Using AI-driven synthetic personas to take your insights fur...

atai Life Sciences

Editor's Picks